pentobarbital will lessen the extent or effect of fosamprenavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital and olopatadine intranasal both enhance sedation. Steer clear of or Use Alternate Drug. Coadministration boosts danger of CNS melancholy, which can cause additive impairment of psychomotor overall performance and bring about daytime impairment.
pentobarbital increases toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inducers might raise the metabolism of ifosfamide to its active alkylating metabolites.
pentobarbital will lower the extent or influence of carvedilol by influencing hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.
pentobarbital will reduce the extent or impact of irinotecan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Reserve concomitant prescribing of these drugs in individuals for whom other procedure possibilities are insufficient. Limit dosages and durations on the minimum amount demanded. Monitor intently for indications of respiratory despair and sedation.
pentobarbital will minimize the extent or impact of voriconazole by influencing hepatic enzyme CYP2C9/10 metabolism. Insignificant/Significance Mysterious.
pentobarbital will minimize the extent or impact of montelukast more info by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.
pentobarbital will lessen the level or impact of sunitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
Withdrawal signs and symptoms may perhaps arise from abrupt cessation after prolonged use from the dependent particular person and should bring about delirium, convulsions, And maybe Dying; barbiturates should be withdrawn steadily from any individual identified to get getting abnormal dosage over extensive amounts of time
Contraindicated (1)pentobarbital will decrease the extent or influence of lorlatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the level or outcome of eucalyptus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
With therapeutic doses of TCAs, barbiturates improve metabolism and decrease blood concentrations of TCAs.
pentobarbital will reduce the level or effect of ramelteon by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unidentified.